文献速递消化系统肿瘤

结直肠癌患者来源类器官释放的游离DNA特征分析

Characterization of the cell-free DNA released by tumor organoids derived from colorectal cancer patients.
PubMed 文献 · Eur J Cancer · 2025-11-05

本研究前瞻性收集13例结直肠癌患者建立的21个患者来源肿瘤类器官(PDTO)培养上清,分析其释放的核游离DNA(cf-nDNA)、线粒体游离DNA(cf-mtDNA)及细胞外线粒体。结果显示95%上清可检出cf-nDNA,片段模式与循环DNA一致,cfDNA突变与PDTO及患者肿瘤突变高度一致(>85%),提示PDTO可模拟患者循环DNA释放。

要点

  • PDTO培养上清可检出核与线粒体游离DNA,片段特征与患者循环DNA相似
  • cfDNA与PDTO及患者肿瘤的致癌突变一致性超过85%
  • PDTO来源cfDNA有望作为非侵入性工具支持功能精准肿瘤学

核心结论

  • PDTO可向培养基释放核与线粒体cfDNA,其片段模式和致癌突变与患者循环DNA高度相似。

研究设计与样本

  • 前瞻性收集13例结直肠癌患者建立的21个PDTO培养上清。
  • 采用qPCR、片段组学和浅层全基因组测序分析cf-nDNA、cf-mtDNA及细胞外线粒体。
  • 通过IntPlex qPCR和全外显子测序(WES)进行突变谱分析。

主要发现

  • 95%的PDTO上清可检出cf-nDNA,浓度范围为0.009至209 ng/mL。
  • cf-nDNA片段大小分析显示与循环DNA一致的模式,包括单核小体相关谱。
  • 所有样本均检出cf-mtDNA(0.27-89.2 pg/mL),并检出细胞外线粒体(0.009-17.4 pg/mL)。
  • cfDNA中的致癌突变与PDTO及患者肿瘤的分子改变一致性超过85%。

临床怎么用

  • PDTO来源cfDNA可作为非侵入性手段研究肿瘤演化,并支持功能精准肿瘤学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patient-derived tumor organoids (PDTOs) have histological, molecular and clinical (drug sensitivity) characteristics comparable to those of their originating tumors. However, little is known about their ability to replicate the release of tumor-derived DNA. METHODS: Supernatants from 21 colorectal cancer PDTO cultures, established from 13 patients, were prospectively collected. The presence, structure, and mutational landscape of nuclear (cf-nDNA) and mitochondrial (cf-mtDNA) cell-free DNA as well as extracellular mitochondria (ex-Mito) were analyzed using qPCR, fragmentomics and shallow whole-genome sequencing. Mutation profiling was performed via IntPlex qPCR and whole-exome sequencing (WES). RESULTS: Cf-nDNA was detected in 95 % of PDTO supernatants with concentrations ranging from 0.009 to 209 ng/mL. Cf-nDNA fragment size analysis revealed patterns consistent with circulating DNA, including mononucleosome-associated profile. Cf-mtDNA was present in all samples (0.27-89.2 pg/mL) and extracellular mitochondria was also detected (0.009-17.4 pg/mL). A strong concordance (>85 %) was observed between oncogenic mutations in cfDNA and the molecular alterations detected in PDTOs and patient tumors. CONCLUSION: PDTOs release both nuclear and mitochondrial cfDNA into their culture medium displaying high similarity with patient-derived circulating DNA (cirDNA), including fragmentation patterns and oncogenic mutations. This study strengthens the relevance of the PDTOs as patient tumors models and highlights the potential of analyzing PDTO-derived cfDNA as a non-invasive approach to investigate tumor evolution and as a valuable tool to support functional precision oncology.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mirandola A, Cartry J, Bedja S, et al. Characterization of the cell-free DNA released by tumor organoids derived from colorectal cancer patients. Eur J Cancer. 2025. PMID: 41223563. doi:10.1016/j.ejca.2025.116097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。